drugset / Trial / NCT06558188
Combined Anabolic Therapy
Phase 4
Recruiting
50 enrolled
Massachusetts General Hospital
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Timeline
- Start
- 2025-02-03
- Primary completion
- 2027-11-02
- Completion
- 2027-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Romosozumab | Monoclonal antibody | 210 mg | — |
| Comparator | Teriparatide | Protein / enzyme biologic | 20 ug | — |